Tibet Rhodiola Pharmaceutical Holding Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
Tibet Rhodiola Pharmaceutical Holding Stock Forecast and Price Target
Given the average yearlong price target of ¥101.22 provided by prominent analysts over the past few months, there is a potential upside of approximately 175.8% from the last closing price in May, 2024 for Tibet Rhodiola Pharmaceutical Holding's stock if it is reached. This estimation is based on a high estimate of ¥113.37 and a low estimate of ¥90.09. If you want to buy 600211 stock, it might be a good idea to look at its competitors too.
175.80% Upside
Tibet Rhodiola Pharmaceutical Holding Fair Value Forecast for 2023 - 2025 - 2030
In the last year, Tibet Rhodiola Pharmaceutical Holding's Price has decreased from ¥113.22 to ¥0.00 – a 100.00% drop. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach ¥202.44 – an increase of 100.00%. Over the next seven years, experts anticipate that Fair Value growth for Tibet Rhodiola Pharmaceutical Holding will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600276 Stock Forecast | Jiangsu Hengrui Medicine | Buy |
15
|
¥46.16 | Buy/Sell | ¥56.49 | 16.98% |
| T14 Stock Forecast | Tianjin Pharmaceutical Da Ren ... | Outperform |
18
|
$34.99 | Buy/Sell | $1.70 | 30.89% |
| 600436 Stock Forecast | Zhangzhou Pientzehuang Pharmac... | Outperform |
18
|
¥237.24 | Buy/Sell | ¥302.86 | 19.10% |
| 000538 Stock Forecast | Yunnan Baiyao Group Co.,Ltd | Outperform |
18
|
¥57.25 | Buy/Sell | ¥65.39 | 11.79% |
| 1093 Stock Forecast | CSPC Pharmaceutical Group | Buy |
18
|
HK$6.76 | Buy/Sell | HK$9.50 | 37.57% |
Tibet Rhodiola Pharmaceutical Holding Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Revenue for Tibet Rhodiola Pharmaceutical Holding has grown by 128.27%, going from ¥1.37B to ¥3.13B. For the following year, the 0 analysts predict that Tibet Rhodiola Pharmaceutical Holding's Revenue will drop by 23.53%, reaching ¥2.40B. In 2030, the professionals' prediction is that 600211's Revenue will decrease by 19.96%, reaching ¥2.51B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 000999 Stock Forecast | China Resources Sanjiu Medical... | Buy |
18
|
¥59.97 | Buy/Sell | ¥65.95 | 13.62% |
| 600085 Stock Forecast | Beijing Tongrentang | Outperform |
16
|
¥42.33 | Buy/Sell | ¥61.18 | 27.57% |
| 600196 Stock Forecast | Shanghai Fosun Pharmaceutical ... | Outperform |
16
|
¥23.67 | Buy/Sell | ¥33.57 | 20.83% |
.jpg)
Tibet Rhodiola Pharmaceutical Holding Dividend per Share Forecast for 2023 - 2025 - 2030
Tibet Rhodiola Pharmaceutical Holding's Dividend per Share has grown in the last three years, jumping from ¥0.51 to ¥1.94 – an increase of 280.39%. In the following year, the 1 analysts surveyed believe that Tibet Rhodiola Pharmaceutical Holding's Dividend per Share will decrease by 100.00%, reaching ¥0.00. According to professionals, by 2030, Tibet Rhodiola Pharmaceutical Holding's Dividend per Share will have decreased by 100.00%, falling down to ¥0.00.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 002294 Stock Forecast | Shenzhen Salubris Pharmaceutic... | Buy |
18
|
¥31.92 | Buy/Sell | ¥35.65 | 15.91% |
| 600079 Stock Forecast | Humanwell Healthcare (Group) | Buy |
0
|
¥20.25 | Buy/Sell | ¥32.49 | -100.00% |
| 000513 Stock Forecast | Livzon Pharmaceutical Group | Outperform |
18
|
¥36.98 | Buy/Sell | ¥39.23 | 11.41% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600518 Stock Forecast | Kangmei Pharmaceutical | - |
6
|
¥1.99 | Buy/Sell | ¥25.97 | -100.00% |
| 300146 Stock Forecast | Byhealth | Outperform |
15
|
¥15.84 | Buy/Sell | ¥26.39 | 29.42% |
| 002262 Stock Forecast | Jiangsu Nhwa Pharmaceutical Co... | Buy |
18
|
¥25.01 | Buy/Sell | ¥31.34 | 23.95% |
Tibet Rhodiola Pharmaceutical Holding EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Tibet Rhodiola Pharmaceutical Holding's EBITDA has grown, increasing from ¥484.95M to ¥1.11B – an increase of 127.92%. For next year, the 1 analysts predict EBITDA of ¥1.69B, which would mean an increase of 52.54%. Over the next seven years, the pros' prediction is EBITDAof ¥1.76B, which would mean a seven-year growth forecast of 59.56%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 900904 Stock Forecast | Shanghai Shenqi Pharmaceutical... | - |
13
|
$6.53 | Buy/Sell | $0.00 | -100.00% |
| 600062 Stock Forecast | China Resources Double-Crane P... | Buy |
16
|
¥21.77 | Buy/Sell | ¥26.00 | 18.24% |
| 600380 Stock Forecast | Joincare Pharmaceutical Group ... | Buy |
18
|
¥11.61 | Buy/Sell | ¥14.72 | 26.79% |
Tibet Rhodiola Pharmaceutical Holding EBIT Forecast for 2023 - 2025 - 2030
Tibet Rhodiola Pharmaceutical Holding's EBIT has increased by 155.01% In the last three years, going from ¥407.32M to ¥1.04B. In the next year, analysts expect EBIT to reach ¥1.63B – an increase of 56.54%. For the next seven years, the forecast is for EBIT to grow by 67.63%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 002773 Stock Forecast | Chengdu Kanghong Pharmaceutica... | Buy |
11
|
¥21.70 | Buy/Sell | ¥24.00 | -100.00% |
| 600867 Stock Forecast | Tonghua Dongbao Pharmaceutical | Buy |
18
|
¥10.09 | Buy/Sell | ¥14.25 | 45.49% |
| 603858 Stock Forecast | Shandong Buchang Pharmaceutica... | - |
18
|
¥16.85 | Buy/Sell | ¥0.00 | -100.00% |
Tibet Rhodiola Pharmaceutical Holding EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, Tibet Rhodiola Pharmaceutical Holding's EPS has decreased from ¥3.16 to ¥0.00 – a 100.00% drop. In the coming year, analysts are expecting an increase in EPS, predicting it will reach ¥5.65 – an increase of 100.00%. Over the next seven years, experts anticipate that EPS growth for Tibet Rhodiola Pharmaceutical Holding will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 000623 Stock Forecast | Jilin Aodong Pharmaceutical Gr... | Buy |
16
|
¥15.28 | Buy/Sell | ¥0.00 | 48.36% |
| 600422 Stock Forecast | KPC Pharmaceuticals,Inc | Buy |
18
|
¥22.72 | Buy/Sell | ¥28.00 | 10.08% |
| 000766 Stock Forecast | Tonghua Golden-Horse Pharmaceu... | - |
11
|
¥17.16 | Buy/Sell | ¥33.00 | -100.00% |
Site Navigation
.jpg)